AVITA Medical (NASDAQ:RCEL) Receives Buy Rating from D. Boral Capital

AVITA Medical (NASDAQ:RCEL)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $22.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 153.75% from the company’s previous close.

A number of other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Lake Street Capital cut their price objective on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

AVITA Medical Trading Down 0.5 %

Shares of RCEL traded down $0.04 during trading hours on Thursday, hitting $8.67. 23,423 shares of the stock traded hands, compared to its average volume of 223,962. AVITA Medical has a 1-year low of $6.90 and a 1-year high of $14.16. The business has a fifty day moving average of $8.89 and a 200-day moving average of $10.46. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39. The firm has a market capitalization of $227.31 million, a PE ratio of -3.63 and a beta of 1.60.

AVITA Medical (NASDAQ:RCEL) last issued its earnings results on Thursday, February 13th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. The business had revenue of $18.41 million for the quarter, compared to the consensus estimate of $18.40 million. Analysts expect that AVITA Medical will post -0.95 EPS for the current year.

Insider Buying and Selling at AVITA Medical

In other news, Director Robert Mcnamara acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average cost of $10.09 per share, for a total transaction of $100,900.00. Following the completion of the acquisition, the director now owns 45,749 shares in the company, valued at $461,607.41. This represents a 27.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.82% of the company’s stock.

Hedge Funds Weigh In On AVITA Medical

A number of large investors have recently bought and sold shares of RCEL. BNP Paribas Financial Markets bought a new stake in shares of AVITA Medical in the fourth quarter worth $38,000. FMR LLC boosted its stake in shares of AVITA Medical by 126.9% during the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after buying an additional 2,376 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of AVITA Medical by 688.9% in the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock valued at $52,000 after acquiring an additional 5,566 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of AVITA Medical by 48.0% in the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock valued at $92,000 after acquiring an additional 2,324 shares during the last quarter. Finally, AlphaQuest LLC increased its position in shares of AVITA Medical by 24.7% in the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company’s stock valued at $120,000 after acquiring an additional 1,858 shares during the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.